You published a review of multiple sclerosis advances in diagnosis and treatment. It was printed in the leading journal Nature Reviews Neurology. Dr. Anton Titov, MD. Your review is titled "Decade in review: multiple sclerosis. New multiple sclerosis medications. Personalized medicine for multiple sclerosis." Dr. Anton Titov, MD. What are leading breakthroughs in personalized medicine for multiple sclerosis treatment? We have the great success with 11 or more multiple sclerosis medicines on the market now. Dr. Paul M. Matthews, MD. These new multiple sclerosis medications give patients and their doctors a wide choice of treatments. Dr. Anton Titov, MD. They are all expensive. It is important to demonstrate clearly that these medications are providing benefits to the patients with multiple sclerosis. Patients are using them in real life. Dr. Paul M. Matthews, MD. We learn from those treatments. We understand who is receiving the most benefits and who might be receiving less benefits. Clinical effectiveness research in multiple sclerosis is taking big strides forward. Neurologists and patients are working together. Two big examples of this were the success of the UK risk-sharing scheme. Dr. Paul M. Matthews, MD. Neurologists all over the country prescribe the first disease-modifying therapy to multiple sclerosis patients. They do so after taking standardized information and recording the progression of disease back to central registry following this standardized therapy choice. Dr. Jackie Palace and her colleagues published earlier in the year a useful summery of this data. They demonstrated clearly how in real life, in the United Kingdom, these multiple sclerosis medicines provide benefit to the patients who take them. In the future, there are new ways of doing data collection through voluntary data aggregation from neurologists all over the world. MS base consortium has been demonstrated this new experience. Dr. Paul M. Matthews, MD. Experts have begun to publish a range of research articles. They demonstrated both the effectiveness of medicines. They showed an ability to provide data on relative effectiveness of multiple sclerosis medications. Dr. Anton Titov, MD. They also showed potentially optimal paths for use of medications. Finally, patients with the progressive multiple sclerosis must be pleased. Dr. Paul M. Matthews, MD. We moved over the last decade from a time when treatment for multiple sclerosis was only about relapsing-remitting form of multiple sclerosis. Now the focus is largely on controlling or stopping progression of multiple sclerosis. The first Phase 2 clinical trial results for remyelination therapy are promising. The first reports of Ocrelizumab have been presented. Ocrelizumab (Ocrevus) is effective in progressive multiple sclerosis. Dr. Anton Titov, MD. There are also many other clinical trials in progress for progressive multiple sclerosis. I think these 10 areas of progress in multiple sclerosis treatment really highlight a huge range of developments in multiple sclerosis. Dr. Paul M. Matthews, MD. New medications will improve prognosis in patients with multiple sclerosis. They will also give us a direction how we can treat other diseases the future. Dr. Anton Titov, MD. They will, indeed. Thank you! This is an excellent review of major advances in multiple sclerosis treatment.